In July I successfully dosed the first Australian patient with tigilanol tiglate at The Kinghorn Cancer Centre, Sydney as part of QBiotics’ multi-centre Phase I/II
Immunotherapy prior to TORS
I have just returned from the 9th International Robotic Surgery Symposium (IRSS) in Seoul, Korea. This is the first in a series of five blog